Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerEBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistanceProstate cancer stem cellsResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerTranslating insights of AR signaling from mouse modelsThe metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways.Overcoming mutation-based resistance to antiandrogens with rational drug designThe potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingA robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinomaEffect of small molecules modulating androgen receptor (SARMs) in human prostate cancer modelsAR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionAndrogen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerThe ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3.Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancerAndrogen Receptor-dependent Expression of Low-density Lipoprotein Receptor-related Protein 6 is Necessary for Prostate Cancer Cell Proliferation.Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activityAndrogen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer CellsDifference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsAdvancing a clinically relevant perspective of the clonal nature of cancerEpigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.Androgen receptor signaling in prostate cancer development and progression.Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signalingSerum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Pharmacogenetics of human androgens and prostate cancer--an update.A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.
P2860
Q21284745-31ABE406-F777-4DB6-9657-7D954A7C80F1Q24646417-DA8E33AB-1035-4CF4-B456-2DD9BD3C97D9Q24654712-F89715D8-B32A-49F6-AA89-54CE2C5A213AQ26751237-82BC8518-761F-4974-9379-B294A13D0BC2Q26773634-12570994-9225-40F5-BEC7-D612EBFE6BE9Q27014822-A8E6593F-6971-43B8-980A-9CD551E4A46EQ27687896-5BADF4A3-EDB9-4500-9928-CAE487E93C68Q28044590-A285BDCE-C9A2-4DB4-ABEB-99151DFEE053Q28087571-5D6C44B9-845F-4092-9577-F867366AB357Q28385552-E2253869-A75B-453F-8729-95AC44373BD1Q28487784-65DB38E3-9D84-4B4F-9442-493C3E56974DQ30513836-C1B5D586-163F-4B07-B62D-93D8149A02E4Q33756662-FF13226D-7F6D-4DC3-9681-6CE51A167EBAQ33823702-D59572B6-C30A-44FF-ADFF-4124E35816C6Q33896008-D3C98F7D-A67E-49AC-B936-60C85F650BADQ33955967-E9EB6102-D7E9-45AA-9FE7-54323AC986CDQ33968384-DC9DDA46-EFBC-4640-BAD4-8839347047F4Q34028361-0E6EB900-5EF4-41BD-BE64-F40A3630A87DQ34043947-934FCF7B-A460-469A-BCC3-450728A814F0Q34055827-B73C14A2-0891-44CD-A6A5-AC66A4CC8166Q34163679-7A5F821E-B028-4173-BBE3-12798D7FF406Q34189517-4487A718-AA42-4611-BC12-27ADEB3E3769Q34248844-B6EF1B41-385F-4743-B290-DDE288A9B976Q34250227-7060AECB-D52F-4268-A270-BCAD0CCCA495Q34417815-169AB4BB-B356-4B4C-8E83-7B4D2600E89BQ34467551-636BE7D7-6540-4832-9094-458E09DF5E8AQ34619574-050B7325-795A-4641-B3DE-1B88181FF0BEQ34793267-F87008C5-5901-46BB-AEB0-97A9850A7442Q35070404-B2770DE7-2EB3-435C-B15A-20D82EE368EEQ35123202-F7A56DED-587A-488A-9359-8CF9F2328790Q35163061-B920C2DF-9650-4541-AD33-5B184CA5082FQ35183663-EA9AD5ED-FE13-4516-816A-58034FDB940FQ35207110-5C70FB5A-ECB6-4F2A-B64F-4E236CD47A96Q35553876-C7320BB7-196F-4C40-9905-BAAAAA7D0882Q35603660-70400DE9-4234-4A88-9ECB-DA705F25898DQ35657424-0D61091B-4B0B-475B-B10E-40756F7E1BF3Q35683334-FD01D039-2B10-4E8A-8B0D-342E044EA00FQ35749654-72232BC5-8CAA-4853-B84C-CC0348987176Q35753329-21C4382B-959D-4161-A5F1-152675C35326Q35754996-8DC9CAD5-0B03-45D8-84CC-9C0997779659
P2860
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Androgen receptor gene amplifi ...... ne refractory prostate cancer.
@en
type
label
Androgen receptor gene amplifi ...... ne refractory prostate cancer.
@en
prefLabel
Androgen receptor gene amplifi ...... ne refractory prostate cancer.
@en
P2093
P2860
P356
P1476
Androgen receptor gene amplifi ...... one refractory prostate cancer
@en
P2093
J M S Bartlett
K M Grigor
N S Krishna
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601127
P407
P577
2003-08-01T00:00:00Z
P5875
P6179
1009634243